AnalystBook Research · Company Intelligence

Bluerock Homes Trust, Inc.

BHMNYSE

Built from Bluerock Homes Trust, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Bluerock Homes grew revenue and cash flow, but its loss widened, debt rose, and equity declined.

The read at a glance✓ Audited against SEC data
  • Business mixResidential communities and scattered homesNote
  • Revenue$68.7M, up 36.9%OK
  • LossesNet loss widened to $32.6MWatch
  • CashFree cash flow improved to $10.4MOK
  • DebtDebt up 14.6%Watch
  • Insiders5 purchases / 0 salesOK
  • AccountingAltman-Z, Beneish-M, and earnings-quality unavailableNote

Business

Bluerock Homes owns residential communities and scattered single-family homes, with an externally managed residential real estate strategy.

Where the revenue comes from

Fiscal 2025, as Bluerock Homes Trust, Inc. reports it. History and quarterly detail are in the app.

  • Residential Communities$37.6M
  • Scattered Single Family Homes$30.6M

Leadership changes

From Bluerock Homes Trust, Inc.'s own filings, the day they're filed.

  • James G. Babb III · departureeff. 2025-12-31

Latest filings

  • 8-K · Company announcement2026-09-02
  • 8-K · Company announcement2026-08-14
  • 10-Q · Quarterly report2026-08-13
  • 8-K · Company announcement2026-08-12
  • 8-K · Company announcement2026-08-11
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Bluerock Homes Trust, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.